Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Thiomorpholine" patented technology

Thiomorpholine, C₄H₉NS, is a heterocyclic compound containing nitrogen and sulfur. It can be considered a thio analog of morpholine.

Crystalline forms of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-N-(tetrahydro-2H-pyran-4-yl)-1H-indol-7-amine

ActiveUS12649730B2Organic active ingredientsCell differentiationThio-Thiomorpholine
The present invention relates to a Crystalline Form A of a compound of Chemical Formula 1 having physically and chemically outstanding characteristics compared to amorphous forms and other crystalline forms of the compound of Chemical Formula 1. Crystalline Form A of the compound of Chemical Formula 1 according to the present invention, compared to amorphous forms or other crystalline forms, does not denature even at prolonged exposure to harsh conditions, has low water sorption, is advantageous for formulation as the crystalline form does not change even under pressure or when pulverized, and the crystalline form itself has excellent stability, being useful for storage for extended periods.
Owner:MITOIMMUNE THERAPEUTICS INC

Heterocyclic derivatives as Janus kinase inhibitors

PendingKR1020260113080ATyrosineRespiratory disease
The present invention relates to compounds that are cyclic carbamate and urea benzo-morpholine and benzo-thiomopoline derivatives of general formula (I) that inhibit the JAK family (JAK1, JAK2, JAK3 and TYK2) of non-receptor tyrosine protein kinases, methods for preparing the compounds, pharmaceutical compositions comprising the compounds, and therapeutic use thereof. The compounds of the present invention may be useful in the treatment of diseases or conditions associated with dysregulation of JAK family non-receptor kinases, particularly in the treatment of various inflammatory diseases including asthma, COPD, and other respiratory diseases.
Owner:키에시파르마슈티시엣스피에이

Crystal form i of benzoxazinooxazolidinone compound otb-658, processes for its preparation, and compositions and uses thereof

ActiveCN120230121BMeet the requirements for clinical useOrganic active ingredientsAntibacterial agentsDiseaseBULK ACTIVE INGREDIENT
The application belongs to the field of pharmacy, and discloses a crystal form I of an oxazolidinone antibacterial candidate new drug OTB-658, a preparation method of the crystal form I, and a composition and application of the crystal form I. Specifically, the application relates to a crystal form I of N-(((3S,3aS)-8-fluoro-1-oxo-7-thiomorpholinyl-3a,4-dihydro-1H,3H-benzo[b]oxazol[3,4-d][1,4]oxazin-3-yl)methyl)acetamide, i.e. OTB-658, and a preparation method of the crystal form I. The crystal form I of OTB-658 is used as a pharmaceutical active ingredient to prepare a drug for treating and / or preventing a bacterial, in particular Mycobacterium tuberculosis, infectious disease.
Owner:BEIJING XIEHE NO2 PHARM FACTORY +1

Thiomorpholino (TMO)-based therapeutics for the treatment of psoriasis and other inflammatory skin diseases

PCT designated stageWO2026136485A1Organic active ingredientsDermatological disorderInflammatory dermatosisThiomorpholine
Use of antisense thiomorpholino oligonucleotides to treat, prevent, or ameliorate the progression of inflammatory skin diseases or conditions such as psoriasis. Specifically, thiomorpholino¬ containing ASOs that target pre-mRNAs associated with inflammatory skin diseases or conditions such as psoriasis.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO